Close Menu

NEW YORK (GenomeWeb) – Invitae announced after the close of the market on Monday that it will offer $125 million worth of its common stock in a public offering.

The San Francisco-based genetic testing firm hasn't finalized the number of shares it will offer of the expected offering price. Its shares were trading down around 5 percent at $19.35 on the New York Stock Exchange on Tuesday morning.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.